Quarterly Report 2 24/25
Diamyd Medical today announces in its second quarterly report for fiscal year 2024/2025 continued progress toward a transformative regulatory milestone, with early Phase 3 results from the DIAGNODE-3 trial expected in March 2026. The trial is on track for full enrollment in 2025, alongside planned GMP certification of the Company’s biomanufacturing facility in Umeå. Following internal strategic discussions and input from its Scientific Advisory Board, Diamyd Medical is also expanding its precision medicine platform and evaluating the inclusion of the LADA (Latent Autoimmune Diabetes in Adults)